Drug intelligence / Profile preview

KT-A522

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intraglandular

Overview

**KT-A522** is an investigational adeno-associated virus (AAV)-based **gene therapy** developed by Kriya Therapeutics for **type 2 diabetes** and **severe obesity**. Administered via **salivary gland injection**, it delivers a gene encoding a **glucagon-like peptide 1 (GLP-1) receptor agonist**, enabling durable endogenous production of the agonist to mimic the effects of injectable GLP-1 therapies like Ozempic or Mounjaro. Originally part of Kriya's early pipeline alongside KT-A112 and KT-A832 for metabolic diseases, it leverages AAV vectors for one-time dosing in prevalent conditions.[1][2][5][7]

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on KT-A522.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT-A522.

Explore the full profile